title: Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease.
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Maier
authors.forename: Briana Q
authors.initials: BQ
authors.lastname: Barkes
authors.forename: Margaret
authors.initials: M
authors.lastname: Mroz
authors.forename: Milton D
authors.initials: MD
authors.lastname: Rossman
authors.forename: Juliana
authors.initials: J
authors.lastname: Barnard
authors.forename: May
authors.initials: M
authors.lastname: Gillespie
authors.forename: Allison
authors.initials: A
authors.lastname: Martin
authors.forename: Douglas G
authors.initials: DG
authors.lastname: Mack
authors.forename: Lori
authors.initials: L
authors.lastname: Silveira
authors.forename: Richard T
authors.initials: RT
authors.lastname: Sawyer
authors.forename: Lee S
authors.initials: LS
authors.lastname: Newman
authors.forename: Andrew P
authors.initials: AP
authors.lastname: Fontenot
mesh_terms: D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001607:Berylliosis / Q000188:drug therapy* / Q000276:immunology; D002908:Chronic Disease; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011788:Quality of Life
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D000069285:Infliximab